Case Report

Primary intradural neuroendocrine tumour of spine: a rare pathology

Vipin K. Gupta¹*, Archit Latawa¹, Gagan Kalra², Bishan D. Radotra³

INTRODUCTION

Neuroendocrine tumours (Carcinoid) are a group of tumours arising from neuroendocrine cells. These tumours commonly involve the gastrointestinal and the respiratory tracts. Uterus, ovaries, urinary bladder, salivary glands and testes are counted among the less common sites of involvement.¹

Central nervous system (CNS) involvement is uncommon and an intradural spinal metastasis is extremely rare. The case discussed here didn't have any history of malignancy and upon investigations no primary tumour was elucidated. To date, only one other case of primary neuroendocrine tumour of the spine has been described in the literature.

CASE REPORT

A 53-year-old female presented to outpatient clinic with progressive weakness of left foot and radicular pain in the left lower limb for past 1 year. The patient also had a history of lower back pain for the past 5 years which aggravated over the last 1 year. No prior history of any malignancy or tuberculosis was there. General physical examination was normal. Upon motor examination, there was overall left ankle weakness. The dorsiflexion power was scored 1/5 and the extensor hallucis longus power was scored 0/5 according to Medical Research Council (MRC) scoring. Left ankle jerk was absent.

ABSTRACT

Neuroendocrine tumour in central nervous system is a very rare pathology. We hereby report a primary intradural neuroendocrine tumour, second to the only other case reported in literature till now as per the best of our knowledge. The tumour was completely intradural, spanning across five segments in the lumbar spine and no primary tumour could be detected elsewhere in body. The patient underwent surgery followed by radiotherapy and showed symptomatic relief. This case report focusses on compiling the available literature on spinal carcinoids (both primary and metastatic) and discussing the relevant investigations and available treatment options for the same.

Keywords: Central nervous system, Intradural, Neuroendocrine tumour, Primary spinal carcinoid

¹Department of Neurosurgery, ²MBBS Student, Government Medical College and Hospital, Chandigarh, Punjab, India
³Department of Pathology, Post Graduate Institute of Medical Education and Research, Chandigarh, Punjab, India

Received: 31 January 2018
Accepted: 06 March 2018

*Correspondence:
Dr. Vipin K. Gupta,
E-mail: vipinkgupta77@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

DOI: http://dx.doi.org/10.18203/2349-2902.isj20181148
Figure 1: T1w sagittal MRI image (A) of lumbar spine showing isodense lesion extending from T12 to L5 with intense contrast enhancement (B).

The tumour was highly vascular and at places a definitive plane of demarcation from the surrounding nerve roots could not be defined, thus a subtotal resection was carried out.

Figure 1: (A) Photomicrograph showing a cellular tumour arranged in nests and trabeculae, separated by thin fibrovascular channels (HE, x200), (B) The tumour cells show strong cytokeratin expression (immunohistochemistry, x200), (C) Diffuse CD56 expression by the tumour cells (immunohistochemistry, x200).

Biopsy of the excised tumour showed a moderately cellular tumour and tumour cells were arranged in nests, islands and ribbons, separated by delicate vascular channels (Figure 2 A). The cells have round to oval nuclei, coarse chromatin, inconspicuous nucleoli and moderate cytoplasm. Prominent vascular proliferation was noted. Mitotic activity was focally increased (3-4/10 high power fields). The tumour stained positive for Pan Cytokeratin (Figure 2 B), CD 56 (Figure 2 C) and faintly positive for synaptophysin. CD 34 showed positivity in the proliferating vessels. However, it was negative for CD 45, GFAP, CK7, TTF1, EMA, GATA3 and CK20. Ki-67 labeling index was 5-6%.

Postoperatively, the patient improved symptomatically. Her radicular pain subsided but there was no improvement in her left lower limb weakness. Contrast enhanced CT scan of chest abdomen and neck didn’t show any primary lesion in thymus, gastrointestinal and respiratory tracts.

Even a whole-body Gallium-68 octreotide (DOTA-NOC) PET scan was carried out 2 months postoperatively which did not reveal any region of excessive uptake anywhere in the body. Only a slight elevation in the biomarker chromogranin A levels was observed, suggestive of some residual disease. So, the patient was subjected to postoperative radiotherapy.

**DISCUSSION**

Neuroendocrine tumours are relatively indolent tumours but uncommonly they may show aggressive course and present with metastatic disease.

Metastatic disease has been noted at presentation in 22% cases of malignant neuroendocrine tumours. Even in patients of advanced stages of neuroendocrine metastasis, involvement of the CNS is very rare, occurring in <2% of the metastases.1,2,3,4

The current case showed no previous history of primary neuroendocrine tumour and contrast enhanced computerized tomography chest, abdomen and neck didn’t show any lesion. For further confirmation, an octreotide scan was done. This scan has been shown to have sensitivity for neuroendocrine tumours between 75% and 100%.1,5 In our case, the scan didn’t show any accumulation along the gastrointestinal tract, the liver, spleen, pancreas, thymus or the genitourinary tract, ruling out any primary tumour site.

Such findings are suggestive that our case represents a primary intradural neuroendocrine tumour. Only one such case has been reported till date. Of all the reported cases of neuroendocrine tumours of the spine, both primary and metastatic, our case represents the largest and most extensive intradural neuroendocrine involvement (spanning over more than 5 vertebral segments). Surgical resection has been shown to be an effective treatment.1,2,6-9 Procedures for spinal decompression and resection of the intradural tumour have been shown to relieve associated pain and limb weakness seen with neuroendocrine tumours of the spinal cord, as in our patient.1,2,6

Neuroendocrine tumours are highly vascular and frequently these tumours have a poor plane of demarcation from the nerve roots. Hence, mostly a
subtotal excision is feasible. Post-operative radiotherapy has been shown to be useful in both preventing recurrence of the tumour and reducing the extent of the residual disease. The role of chemotherapy in these tumours is not clear. A high index of clinical suspicion needs to be kept for neuroendocrine metastases to the spinal cord as it is a rare differential diagnosis for spinal masses detected on CT or MRI. Octreoscan (DOTA-DOC) is a useful investigation with a very high sensitivity and specificity for neuroendocrine tumours. Chromogranin A level is an important laboratory investigation that is shown to be useful, as it is the most common tumour marker for neuroendocrine tumours.

CONCLUSION

To conclude, primary neuroendocrine tumour of the spine is very rare pathology. We have tried to compile the thorough literature available, so that our current knowledge about this entity can be enhanced.

**REFERENCES**


<table>
<thead>
<tr>
<th>Table 1: Showing primary and secondary neuroendocrine tumours of central nervous system described in literature.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Report</strong></td>
</tr>
<tr>
<td><strong>Intradural neuroendocrine metastasis</strong></td>
</tr>
<tr>
<td>Ironside et al12</td>
</tr>
<tr>
<td>Rao et al6</td>
</tr>
<tr>
<td>Hopster et al7</td>
</tr>
<tr>
<td>Blondet et al8</td>
</tr>
<tr>
<td>Nagel et al9</td>
</tr>
<tr>
<td>Karatas et al10</td>
</tr>
<tr>
<td>Camarero C et al9</td>
</tr>
<tr>
<td><strong>Primary intradural neuroendocrine tumour</strong></td>
</tr>
<tr>
<td>Audlin et al1</td>
</tr>
<tr>
<td>Current case</td>
</tr>
</tbody>
</table>

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

**CONCLUSION**

To conclude, primary neuroendocrine tumour of the spine is very rare pathology. We have tried to compile the thorough literature available, so that our current knowledge about this entity can be enhanced.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


Cite this article as: Gupta VK, Latawa A, Kalra G, Radotra BD. Primary intradural neuroendocrine tumour of spine: a rare pathology. Int Surg J 2018;5:1567-70.